Tyrosine kinase inhibitorFDA-approvedSecond-line
Dasatinib
How it works
Blocks the activity of BCR-ABL tyrosine kinase, a protein that drives cancer cell growth in chronic myeloid leukemia (CML).
Cancer types
Leukemia— BCR-ABL-positive
Efficacy
Studies show that dasatinib can induce a complete cytogenetic response in around 70% of CML patients, with a median progression-free survival of approximately 4 years.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Chronic Leukemia Relapse After Bone Marrow Transplantation | Leukemia | observational | — | Source → |
| Improving Cancer Treatment with Targeted Drug Delivery | Leukemia | lab-study | — | Source → |
| Rare Complication in Cancer Patients on Dasatinib Therapy | Leukemia | observational | — | Source → |
| Woman Develops Lung Injury After Taking Cancer Drug Dasatinib | Leukemia | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.